Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $54.96 USD
Change Today -0.53 / -0.96%
Volume 60.5K
WST On Other Exchanges
New York
As of 12:29 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

west pharmaceutical services (WST) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/31/15 - $60.30
52 Week Low
08/12/14 - $39.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

west pharmaceutical services (WST) Related Businessweek News

No Related Businessweek News Found

west pharmaceutical services (WST) Details

West Pharmaceutical Services, Inc. develops, manufactures, and sells components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The company operates through two segments, Pharmaceutical Packaging Systems and Pharmaceutical Delivery Systems. The Pharmaceutical Packaging Systems segment offers packaging components and systems for injectable drug delivery, such as stoppers and seals for vials, closures and other components used in syringe, intravenous and blood collection systems, and prefillable syringe components. This segment also provides contract analytical laboratory services for testing and evaluating primary drug-packaging components with the contained drug formulation; and specialized testing for complete drug delivery systems. The Pharmaceutical Delivery Systems segment offers safety and administration systems, and multi-component systems for drug administration. It offers customer contract-manufacturing and assembly solutions, which include technologies, such as multi-component molding, in-mold labeling, ultrasonic welding, and clean room molding and device assembly used to manufacture customer-owned components, as well as devices used in surgical, diagnostic, ophthalmic, other drug delivery systems, personal care, and consumer products. This segment’s administration systems comprise sterile devices for the administration of drug products, including transfer devices, needleless reconstitution systems, and vial adapters. The company sells its products primarily through its sales force and distribution network, as well as through contract sales agents and regional distributors in the United States, Germany, France, and other European countries. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

7,000 Employees
Last Reported Date: 02/25/15
Founded in 1923

west pharmaceutical services (WST) Top Compensated Officers

Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $467.0K
President of Pharmaceutical Delivery Systems
Total Annual Compensation: $350.3K
President of the Pharmaceutical Packaging Sys...
Total Annual Compensation: $346.0K
President of Pharmaceutical Packaging Systems...
Total Annual Compensation: $339.1K
Compensation as of Fiscal Year 2014.

west pharmaceutical services (WST) Key Developments

West Pharmaceutical Services, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 02:20 PM

West Pharmaceutical Services, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 02:20 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States.

West Pharmaceutical Services, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Year 2015

West Pharmaceutical Services, Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. The company reported revenues were $335.9 million versus $346.8 million in the prior year period. In constant exchange rates, sales actually grew by 6.5%, driven by demand for high-value products in North America and Europe. Operating cash flow was a negative $2 million in the current quarter, $11 million less than the prior year quarter, reflecting the voluntary $20 million pension contribution made in the first quarter of 2015. Capital spending was $30.4 million in the current quarter. Adjusted net income grew by more than 21%, resulting in earnings per fully diluted share of $0.45, an 18.4% increase. The increase in diluted EPS was achieved despite the decline in the value of the euro, which reduced reported earnings by $0.08 per share. Operating profit was $47.8 million against $39.3 million a year ago. Income before income taxes was $44.1 million against $35.7 million a year ago. Net income was $32.9 million or $0.45 per diluted share against $27.1 million or $0.38 per diluted share a year ago. Debt at March 31 was $330.7 million, $6 million less than at year end. For the full year of 2015, sales will again be driven by high-value products for biologics, rising sales of proprietary devices and sample requirements for ongoing development programs utilizing CZ and SmartDose. Although the underlying organic growth of business will be healthy, full year sales and earnings will be subject to the currency headwind from the strong U.S. dollar. Assuming an exchange rate of $1.08 for the remainder of the year, currency translation would be expected to reduce sales by approximately $120 million and adjusted diluted EPS by $0.23 to $0.25 per share. On that basis, the company estimates 2015 adjusted earnings per share will fall in the range of $1.69 to $1.84. The estimated annual effective tax rate for 2015 is 28.4%, compared with 27.0% in 2014. The increase in the ETR is attributable to expiration of the U.S. credit for increasing research activities and the impact of shifts in the geographic mix of earnings and tax rates, which is attributable in part to the stronger U.S. dollar. For the full year 2015, the company continues to expect year-over-year revenue growth in the 6% to 8% range, excluding currency, although visibility into the second half of the year is somewhat limited. Consolidated net sales are expected to be $1,395 to $1,425 compared to previous guidance of $1,430 to $1,460. The Company estimates its 2015 capital spending at between $145 million and $160 million, including approximately $25 million related to the planned new facility in Waterford, Ireland.

West Pharmaceutical Services, Inc. Presents at UBS Global Healthcare Conference, May-18-2015 03:30 PM

West Pharmaceutical Services, Inc. Presents at UBS Global Healthcare Conference, May-18-2015 03:30 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Donald E. Morel, Chairman, Eric M. Green, Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WST:US $54.96 USD -0.53

WST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chemed Corp $122.94 USD -0.39
Gerresheimer AG €53.31 EUR +0.039
IDEXX Laboratories Inc $134.93 USD -2.41
Sirona Dental Systems Inc $99.70 USD +0.44
STERIS Corp $65.62 USD -0.52
View Industry Companies

Industry Analysis


Industry Average

Valuation WST Industry Range
Price/Earnings 29.7x
Price/Sales 2.7x
Price/Book 4.1x
Price/Cash Flow 29.2x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WEST PHARMACEUTICAL SERVICES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at